Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 1;109(7):1904-7.
doi: 10.1038/bjc.2013.542. Epub 2013 Sep 5.

Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan

K Nouso  1 , K Miyahara, D Uchida, K Kuwaki, N Izumi, M Omata, T Ichida, M Kudo, Y Ku, N Kokudo, M Sakamoto, O Nakashima, T Takayama, O Matsui, Y Matsuyama, K Yamamoto; Liver Cancer Study Group of Japan
Affiliations

Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan

K Nouso et al. Br J Cancer. .

Abstract

Background: The efficacy of hepatic arterial infusion chemotherapy for the treatment of advanced hepatocellular carcinoma (HCC) remains unclear.

Methods: The outcome of 476 patients with HCC who underwent hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin (HAIC) were compared with 1466 patients who did not receive active therapy.

Results: A survival benefit of the therapy after adjusting for known risk factors was observed (hazard ratio, 0.48; 95% CI, 0.41-0.56; P<0.0001). In propensity score-matched analysis (n=682), median survival time was longer for patients who underwent chemotherapy (14.0 months) than for patients who did not receive active treatment (5.2 months, P<0.0001).

Conclusion: For advanced HCC, HAIC is considered to be an effective treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival of patients who underwent hepatic arterial infusion of 5-fluorouracil and cisplatin using a subcutaneous infusion port. The 1- and 3-year survival rates and median survival times according to response were as follows: CR/PR (77.7%, 34.6%, 25.8 months), SD (44.2%, 13.3%, 9.5 months), and PD (23.7%, 10.3%, 6.0 months) (P<0.0001). Abbreviations: CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease.
Figure 2
Figure 2
Survival of propensity score-matched patients who underwent hepatic arterial infusion of 5-fluorouracil and cisplatin (HAIC) or no active therapy (no therapy). Median survival times were 14.0 months (HAIC) and 5.2 months (no therapy) (P<0.0001).
See this image and copyright information in PMC

References

    1. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95 (3:588–595. - PubMed
    1. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25 (12:2084–2106. - PubMed
    1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10 (1:25–34. - PubMed
    1. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol. 2009;44 (12:1477–1486. - PubMed
    1. European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48 (5:599–641. - PubMed

Publication types

MeSH terms